PortfoliosLab logoPortfoliosLab logo
REGN vs. BAESY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

REGN vs. BAESY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Regeneron Pharmaceuticals, Inc. (REGN) and BAE Systems PLC (BAESY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, REGN achieves a -20.58% return, which is significantly lower than BAESY's 12.98% return. Over the past 10 years, REGN has underperformed BAESY with an annualized return of 5.18%, while BAESY has yielded a comparatively higher 18.73% annualized return.


REGN

1D
-3.79%
1M
-14.36%
YTD
-20.58%
6M
-12.84%
1Y
24.63%
3Y*
-6.19%
5Y*
3.39%
10Y*
5.18%

BAESY

1D
0.88%
1M
-2.16%
YTD
12.98%
6M
13.84%
1Y
0.14%
3Y*
31.96%
5Y*
30.90%
10Y*
18.73%
*Multi-year figures are annualized to reflect compound growth (CAGR)

REGN vs. BAESY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
REGN
Regeneron Pharmaceuticals, Inc.
-20.58%8.96%-18.90%21.73%14.25%30.72%28.66%0.53%-0.65%2.42%
BAESY
BAE Systems PLC
12.98%65.51%1.23%40.91%46.40%14.56%-3.43%34.69%-22.16%13.28%

Correlation

The correlation between REGN and BAESY is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.09

Correlation (5Y)
Calculated over the trailing 5-year period

0.09

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Jul 16, 2007

0.17

Fundamentals

Market Cap

REGN:

$65.84B

BAESY:

$78.73B

EPS

REGN:

$41.05

BAESY:

$5.29

PE Ratio

REGN:

14.89

BAESY:

19.61

PS Ratio

REGN:

4.42

BAESY:

1.44

PB Ratio

REGN:

2.10

BAESY:

6.69

Total Revenue (TTM)

REGN:

$14.92B

BAESY:

$54.56B

Gross Profit (TTM)

REGN:

$12.61B

BAESY:

$19.72B

EBITDA (TTM)

REGN:

$5.74B

BAESY:

$7.74B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

REGN vs. BAESY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REGN
REGN Risk / Return Rank: 6464
Overall Rank
REGN Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
REGN Sortino Ratio Rank: 6161
Sortino Ratio Rank
REGN Omega Ratio Rank: 6060
Omega Ratio Rank
REGN Calmar Ratio Rank: 6262
Calmar Ratio Rank
REGN Martin Ratio Rank: 6969
Martin Ratio Rank

BAESY
BAESY Risk / Return Rank: 4040
Overall Rank
BAESY Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
BAESY Sortino Ratio Rank: 3737
Sortino Ratio Rank
BAESY Omega Ratio Rank: 3535
Omega Ratio Rank
BAESY Calmar Ratio Rank: 4242
Calmar Ratio Rank
BAESY Martin Ratio Rank: 4242
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

REGN vs. BAESY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and BAE Systems PLC (BAESY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


REGNBAESYDifference
Sharpe ratioReturn per unit of total volatility

+0.74

Sortino ratioReturn per unit of downside risk

+1.02

Omega ratioGain probability vs. loss probability

1.16

1.03

+0.13

Calmar ratioReturn relative to maximum drawdown

0.96

0.01

+0.95

Martin ratioReturn relative to average drawdown

3.20

0.01

+3.18

REGN vs. BAESY - Sharpe Ratio Comparison

The current REGN Sharpe Ratio is 0.75, which is higher than the BAESY Sharpe Ratio of 0.00. The chart below compares the historical Sharpe Ratios of REGN and BAESY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


REGNBAESYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.75

0.00

+0.74

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.11

1.11

-1.00

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.16

0.67

-0.51

Sharpe Ratio (All Time)

Calculated using the full available price history

0.16

0.35

-0.19

Drawdowns

REGN vs. BAESY - Drawdown Comparison

The maximum REGN drawdown since its inception was -91.81%, which is greater than BAESY's maximum drawdown of -59.20%. Use the drawdown chart below to compare losses from any high point for REGN and BAESY.


Loading charts...

Drawdown Indicators


REGNBAESYDifference

Max Drawdown

Largest peak-to-trough decline

-91.81%

-59.20%

-32.61%

Max Drawdown (1Y)

Largest decline over 1 year

-25.85%

-23.59%

-2.26%

Max Drawdown (3Y)

Largest decline over 3 years

-59.69%

-23.59%

-36.10%

Max Drawdown (5Y)

Largest decline over 5 years

-59.69%

-23.59%

-36.10%

Max Drawdown (10Y)

Largest decline over 10 years

-59.69%

-42.13%

-17.56%

Current Drawdown

Current decline from peak

-48.71%

-15.62%

-33.09%

Average Drawdown

Average peak-to-trough decline

-42.39%

-19.33%

-23.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.73%

9.99%

-2.26%

Volatility

REGN vs. BAESY - Volatility Comparison

Regeneron Pharmaceuticals, Inc. (REGN) has a higher volatility of 12.61% compared to BAE Systems PLC (BAESY) at 9.80%. This indicates that REGN's price experiences larger fluctuations and is considered to be riskier than BAESY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


REGNBAESYDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.61%

9.80%

+2.81%

Volatility (6M)

Calculated over the trailing 6-month period

22.61%

24.82%

-2.21%

Volatility (1Y)

Calculated over the trailing 1-year period

33.09%

31.94%

+1.15%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

30.82%

28.05%

+2.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

32.18%

27.88%

+4.30%

Dividends

REGN vs. BAESY - Dividend Comparison

REGN's dividend yield for the trailing twelve months is around 0.60%, less than BAESY's 1.87% yield.


PositionTTM20252024202320222021202020192018201720162015
BAESY
BAE Systems PLC
1.87%1.90%2.79%2.40%3.09%4.46%7.05%3.66%4.93%5.71%6.26%4.38%
REGN
Regeneron Pharmaceuticals, Inc.
0.60%0.46%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

REGN vs. BAESY - Financials Comparison

This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and BAE Systems PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


2.00B4.00B6.00B8.00B10.00B12.00B14.00B20222023202420252026
3.61B
14.67B
(REGN) Total Revenue
(BAESY) Total Revenue
Values in USD except per share items

REGN vs. BAESY - Profitability Comparison

The chart below illustrates the profitability comparison between Regeneron Pharmaceuticals, Inc. and BAE Systems PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
81.4%
9.2%
Portfolio components
REGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.

BAESY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BAE Systems PLC reported a gross profit of 1.34B and revenue of 14.67B. Therefore, the gross margin over that period was 9.2%.

REGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.

BAESY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BAE Systems PLC reported an operating income of 1.34B and revenue of 14.67B, resulting in an operating margin of 9.2%.

REGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.

BAESY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BAE Systems PLC reported a net income of 1.09B and revenue of 14.67B, resulting in a net margin of 7.4%.


Frequently Asked Questions


REGN and BAESY have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

REGN has higher volatility (12.61%) compared to BAESY (9.80%). In terms of maximum drawdown, REGN dropped -91.81% vs BAESY's -59.20%.

REGN currently has the higher Sharpe Ratio (0.75 vs 0.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for REGN and BAESY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer